McKesson Stock: Is Wall Street Bullish or Bearish?
/Mckesson%20Corporation%20website-by%20chrisdorney%20via%20Shutterstock.jpg)
With a market cap of $89.9 billion, McKesson Corporation (MCK) is a global leader in healthcare services and information technology. The company operates through four main segments - U.S. Pharmaceutical; Prescription Technology Solutions; Medical-Surgical Solutions; and International, delivering pharmaceuticals, medical supplies, and technology-driven solutions across the healthcare industry.
Shares of the Irving, Texas-based company have outperformed the broader market over the past 52 weeks. MCK has increased 30.1% over this time frame, while the broader S&P 500 Index ($SPX) has gained 9.8%. Moreover, McKesson stock has risen 26.1% on a YTD basis, compared to SPX's marginal decline.
Looking closer, the storied healthcare supplies company has also outpaced the Health Care Select Sector SPDR Fund's (XLV) 10% decrease over the past 52 weeks.
Shares of MCK recovered marginally following its Q4 2025 earnings release on May 8. The company reported a 19% year-over-year increase in revenue to $90.8 billion and a 15% rise in adjusted net income to nearly $1.3 billion or $10.12 per share. Although results slightly missed analyst expectations in revenue, earnings beat the forecast. Additionally, positive sentiment was supported by upbeat fiscal 2026 guidance of $36.75 - $37.55 in adjusted EPS and plans to spin off the Medical-Surgical Solutions unit into a standalone company.
For the fiscal year ending in March 2026, analysts expect MCK’s adjusted EPS to grow 12.9% year-over-year to $37.30. The company's earnings surprise history is mixed. It topped the consensus estimates in three of the last four quarters while missing on another occasion.
Among the 17 analysts covering the stock, the consensus rating is a “Strong Buy.” That’s based on 13 “Strong Buy” ratings and four “Holds.”
On May 9, Jefferies analyst Rob Dickerson raised McKesson’s price target to $800 and reiterated a “Buy" rating, citing the company’s strong Q4 results.
As of writing, MCK is trading below the mean price target of $756.25. The Street-high price target of $820 implies a modest potential upside of 14.1% from the current price levels.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.